Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_513c19bd2e56525eaacdda8e0ec06a1d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-922 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
filingDate |
2017-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_662c59a70b5ebe6678040e1bb0dd3e96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56f4f6f6167224f4092aeff6839bd9ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dce7f6ffdca0a85202a2b960925492a2 |
publicationDate |
2017-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-3015353-A1 |
titleOfInvention |
Viral and oncoviral nuclease treatment |
abstract |
Compositions and methods for treating infection-associated cancer include the use of a nuclease that cuts nucleic acid of an oncovirus in combination with an adjunct chemo therapeutic that treats cancerous cells. For example, a Cas9 endonuclease and a guide RNA that matches a target in a viral genome without having any corresponding match in the human genome can be delivered along with an anti-apoptotic inhibitor. Embodiments treat a viral infection and use a nuclease and an inhibitor that prevents DNA repair, such as a CRISPR-associated nuclease and a small molecule that inhibits an enzyme of a repair pathway. Under guidance of a targeting sequence, the nuclease cuts viral nucleic acid without cutting the patient's genome. The cut ends of the viral nucleic acid are not repaired because the inhibitor prevents a repair mechanism. |
priorityDate |
2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |